Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- September 11, 2019 Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
- September 9, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- September 3, 2019 Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
- August 28, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- August 28, 2019 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- August 16, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- July 31, 2019 Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
- July 26, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- July 22, 2019 Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
- July 18, 2019 Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
Displaying 231 - 240 of 306